Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla

Pier Alberto Testoni, Fausto Lella, Francesco Bagnolo, Salvatore Caporuscio, Laila Cattani, Elena Colombo, Mario Buizza

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The pancreas commonly reacts to endoscopic papillosphincterotomy (EST) with a rise in serum amylase, and acute pancreatitis may also develop. The long-acting somatostatin analogue octreotide has recently been proposed for prevention of colangiopancreatography (ERCP)/EST-induced pancreatic reaction. Therefore, we tested the prophylactic effects of a subcutaneous 3-day administration of octreotide to 60 consecutive patients undergoing ERCP and EST. They were randomly allocated to receive either 200 μg octreotide t.i.d. for 3 days (30 cases) or placebo (control group, 30 cases) before the procedure. On the day of the examination, serum amylase levels were determined at baseline and 2, 4, 8, and 24 h thereafter. In the patients as a whole, the increases were statistically significant at 4 h (p <0.01) and 8 h (p <0.01). Epigastric pain occurred in 2 patients in the octreotide group and in 13 control subjects (p <0.001). Even in some patients who had had previous episodes of relapsing pancreatitis, the rise in serum amylase was significantly lower in the octreotide group than in the control group at 4 h (p <0.01). 8 h (p = 0.05), and 24 h (p = 0.05). Our data suggest that 3 days of prophylactic treatment with octreotide is effective for reducing the rise in serum amylase after EST/ERCP and could be proposed for patients with relapsing pancreatitis and other risk conditions before the Vater's papilla manipulation.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalPancreas
Volume13
Issue number1
Publication statusPublished - 1996

Fingerprint

Octreotide
Amylases
Endoscopic Retrograde Cholangiopancreatography
Serum
Pancreatitis
Control Groups
Somatostatin
Pancreas
Placebos
Pain

Keywords

  • Acute pancreatitis
  • Endoscopic papillosphincterotomy
  • Octreotide
  • Pancreatic reaction

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology

Cite this

Testoni, P. A., Lella, F., Bagnolo, F., Caporuscio, S., Cattani, L., Colombo, E., & Buizza, M. (1996). Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas, 13(1), 61-65.

Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. / Testoni, Pier Alberto; Lella, Fausto; Bagnolo, Francesco; Caporuscio, Salvatore; Cattani, Laila; Colombo, Elena; Buizza, Mario.

In: Pancreas, Vol. 13, No. 1, 1996, p. 61-65.

Research output: Contribution to journalArticle

Testoni, PA, Lella, F, Bagnolo, F, Caporuscio, S, Cattani, L, Colombo, E & Buizza, M 1996, 'Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla', Pancreas, vol. 13, no. 1, pp. 61-65.
Testoni, Pier Alberto ; Lella, Fausto ; Bagnolo, Francesco ; Caporuscio, Salvatore ; Cattani, Laila ; Colombo, Elena ; Buizza, Mario. / Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. In: Pancreas. 1996 ; Vol. 13, No. 1. pp. 61-65.
@article{b78e8079d9a34c1c8a3b9e3af263317d,
title = "Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla",
abstract = "The pancreas commonly reacts to endoscopic papillosphincterotomy (EST) with a rise in serum amylase, and acute pancreatitis may also develop. The long-acting somatostatin analogue octreotide has recently been proposed for prevention of colangiopancreatography (ERCP)/EST-induced pancreatic reaction. Therefore, we tested the prophylactic effects of a subcutaneous 3-day administration of octreotide to 60 consecutive patients undergoing ERCP and EST. They were randomly allocated to receive either 200 μg octreotide t.i.d. for 3 days (30 cases) or placebo (control group, 30 cases) before the procedure. On the day of the examination, serum amylase levels were determined at baseline and 2, 4, 8, and 24 h thereafter. In the patients as a whole, the increases were statistically significant at 4 h (p <0.01) and 8 h (p <0.01). Epigastric pain occurred in 2 patients in the octreotide group and in 13 control subjects (p <0.001). Even in some patients who had had previous episodes of relapsing pancreatitis, the rise in serum amylase was significantly lower in the octreotide group than in the control group at 4 h (p <0.01). 8 h (p = 0.05), and 24 h (p = 0.05). Our data suggest that 3 days of prophylactic treatment with octreotide is effective for reducing the rise in serum amylase after EST/ERCP and could be proposed for patients with relapsing pancreatitis and other risk conditions before the Vater's papilla manipulation.",
keywords = "Acute pancreatitis, Endoscopic papillosphincterotomy, Octreotide, Pancreatic reaction",
author = "Testoni, {Pier Alberto} and Fausto Lella and Francesco Bagnolo and Salvatore Caporuscio and Laila Cattani and Elena Colombo and Mario Buizza",
year = "1996",
language = "English",
volume = "13",
pages = "61--65",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla

AU - Testoni, Pier Alberto

AU - Lella, Fausto

AU - Bagnolo, Francesco

AU - Caporuscio, Salvatore

AU - Cattani, Laila

AU - Colombo, Elena

AU - Buizza, Mario

PY - 1996

Y1 - 1996

N2 - The pancreas commonly reacts to endoscopic papillosphincterotomy (EST) with a rise in serum amylase, and acute pancreatitis may also develop. The long-acting somatostatin analogue octreotide has recently been proposed for prevention of colangiopancreatography (ERCP)/EST-induced pancreatic reaction. Therefore, we tested the prophylactic effects of a subcutaneous 3-day administration of octreotide to 60 consecutive patients undergoing ERCP and EST. They were randomly allocated to receive either 200 μg octreotide t.i.d. for 3 days (30 cases) or placebo (control group, 30 cases) before the procedure. On the day of the examination, serum amylase levels were determined at baseline and 2, 4, 8, and 24 h thereafter. In the patients as a whole, the increases were statistically significant at 4 h (p <0.01) and 8 h (p <0.01). Epigastric pain occurred in 2 patients in the octreotide group and in 13 control subjects (p <0.001). Even in some patients who had had previous episodes of relapsing pancreatitis, the rise in serum amylase was significantly lower in the octreotide group than in the control group at 4 h (p <0.01). 8 h (p = 0.05), and 24 h (p = 0.05). Our data suggest that 3 days of prophylactic treatment with octreotide is effective for reducing the rise in serum amylase after EST/ERCP and could be proposed for patients with relapsing pancreatitis and other risk conditions before the Vater's papilla manipulation.

AB - The pancreas commonly reacts to endoscopic papillosphincterotomy (EST) with a rise in serum amylase, and acute pancreatitis may also develop. The long-acting somatostatin analogue octreotide has recently been proposed for prevention of colangiopancreatography (ERCP)/EST-induced pancreatic reaction. Therefore, we tested the prophylactic effects of a subcutaneous 3-day administration of octreotide to 60 consecutive patients undergoing ERCP and EST. They were randomly allocated to receive either 200 μg octreotide t.i.d. for 3 days (30 cases) or placebo (control group, 30 cases) before the procedure. On the day of the examination, serum amylase levels were determined at baseline and 2, 4, 8, and 24 h thereafter. In the patients as a whole, the increases were statistically significant at 4 h (p <0.01) and 8 h (p <0.01). Epigastric pain occurred in 2 patients in the octreotide group and in 13 control subjects (p <0.001). Even in some patients who had had previous episodes of relapsing pancreatitis, the rise in serum amylase was significantly lower in the octreotide group than in the control group at 4 h (p <0.01). 8 h (p = 0.05), and 24 h (p = 0.05). Our data suggest that 3 days of prophylactic treatment with octreotide is effective for reducing the rise in serum amylase after EST/ERCP and could be proposed for patients with relapsing pancreatitis and other risk conditions before the Vater's papilla manipulation.

KW - Acute pancreatitis

KW - Endoscopic papillosphincterotomy

KW - Octreotide

KW - Pancreatic reaction

UR - http://www.scopus.com/inward/record.url?scp=0029888404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029888404&partnerID=8YFLogxK

M3 - Article

C2 - 8783335

AN - SCOPUS:0029888404

VL - 13

SP - 61

EP - 65

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 1

ER -